Is BSX a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Farapulse and the Pulsed Field Ablation Wave, with revenue (ttm) at ~$21 billion (+7.5% YoY in Q2 2026). The bear case rests on the most immediate concern is a run of setbacks in 2026. Analysts covering it are spread from $44.00 to $94.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The most immediate concern is a run of setbacks in 2026. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $44.00, -0.9% from the $44.39 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Farapulse and the Pulsed Field Ablation Wave. The Farapulse pulsed field ablation (PFA) system remains the most important growth driver, helping the electrophysiology business post roughly 37% year-over-year growth in the fourth quarter of 2025. The most optimistic analyst target on BSX is $94.00, +111.8% from the $44.39 price. That figure is only reachable if this thesis works close to its best case.

The most immediate concern is a run of setbacks in 2026. Management lowered its profit outlook in July on weaker Watchman demand and US electrophysiology share losses, then in September said a cybersecurity incident had disrupted manufacturing and order shipments and that it was unlikely to meet its third-quarter and full-year sales and adjusted earnings forecasts. In October it recalled 262,686 Imager II angiographic catheters because the tip may fracture or detach during use, a reminder of the product-recall and safety-signal risk inherent to medical devices. Competition is intensifying as Medtronic and Johnson and Johnson scale their own pulsed field ablation systems, which could further erode Boston Scientific's early PFA share and pressure pricing. Brokers including Baird, Truist and Mizuho trimmed price targets in mid-October 2026. Foreign exchange swings, hospital capital-spending cycles, reimbursement or regulatory changes, about $12.6 billion of debt, and integration risk from the company's acquisition strategy each add uncertainty. The most pessimistic published target is $44.00, -0.9% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Boston Scientific Corporation is a Marlborough, Massachusetts-based medical device company that develops, manufactures, and markets minimally invasive devices used in interventiona

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Farapulse and the Pulsed Field Ablation Wave) stalling in the reported numbers rather than in the narrative, the risk above (the most immediate concern is a run of setbacks in 2026) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Boston Scientific develops and sells minimally invasive medical devices used in interventional cardiology, electrophysiology, structural heart, peripheral interventions, endoscopy, urology, and neuromodulation. It reports through two segments, Cardiovascular and MedSurg, and sells to hospitals and physicians in roughly 130 countries. Its highest-profile products include the Farapulse pulsed field ablation system and the Watchman heart-implant device.

That depends on your horizon and risk tolerance, and Walnut does not make that call. Boston Scientific still earns about $3.7 billion a year and trades at roughly 18x trailing and 13x forward earnings, far below its historical premium after a decline of more than 50% in 2026. However, management cut its 2026 outlook in July, warned again after a September cybersecurity incident, and competition in pulsed field ablation is costing it US share. Investors weigh those trade-offs differently.

Boston Scientific has historically reinvested cash into research, development, and acquisitions rather than paying a regular dividend, positioning itself as a growth-oriented medical device company. Investors in BSX have generally sought total return from share-price appreciation rather than income. Always confirm the current dividend policy with your broker or the company's investor relations page before investing.